Revenues from the Life Sciences business unit, which is on track to be sold to Waters in Q1 2026, rose 2 percent to $1.37 billion.

The firm said that growth in its immunodiagnostics business was offset by contraction in its molecular diagnostics, licensed technologies, and COVID-19 businesses.

Third quarter revenues dipped 4 percent as reported but rose 5 percent excluding results from COVID-19 testing and the donor screening business the firm is exiting.

Parent firm Siemens is considering reducing its ownership stake in Siemens Healthineers, which could mean the termination of existing financing agreements.

For the fourth quarter, the point-of-care diagnostics company anticipates revenues of between $25 million and $28 million.

These drugs, which are among the most common types of blood thinners, can interfere with traditional coagulation tests, producing unreliable results.

The firm's data and services revenues grew 26 percent to $81.3 million, while genomics revenues more than doubled to $252.9 million.

The French in vitro diagnostics company slightly lowered its full-year revenue guidance to adjust for a late respiratory infection season.

The next-generation sequencing-based test is designed to capture all clinically relevant cystic fibrosis mutations in a single assay.

The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.

Last week, readers were most interested in a story about Biodesix's journey as a publicly traded company and what lies ahead for it.

Of the 30 companies in the index, 21 firms saw their share prices rise month over month, while nine saw their stock prices decline.